DongKook Pharmaceutical Co., Ltd.

KOSDAQ:A086450 Stock Report

Market Cap: ₩734.7b

DongKook Pharmaceutical Past Earnings Performance

Past criteria checks 4/6

DongKook Pharmaceutical's earnings have been declining at an average annual rate of -2.2%, while the Pharmaceuticals industry saw earnings growing at 7.5% annually. Revenues have been growing at an average rate of 9.8% per year. DongKook Pharmaceutical's return on equity is 9.7%, and it has net margins of 7.8%.

Key information

-2.2%

Earnings growth rate

-2.2%

EPS growth rate

Pharmaceuticals Industry Growth11.3%
Revenue growth rate9.8%
Return on equity9.7%
Net Margin7.8%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

DongKook Pharmaceutical Co., Ltd. (KOSDAQ:086450) Investors Are Less Pessimistic Than Expected

Aug 07
DongKook Pharmaceutical Co., Ltd. (KOSDAQ:086450) Investors Are Less Pessimistic Than Expected

These 4 Measures Indicate That DongKook Pharmaceutical (KOSDAQ:086450) Is Using Debt Reasonably Well

May 29
These 4 Measures Indicate That DongKook Pharmaceutical (KOSDAQ:086450) Is Using Debt Reasonably Well

We Think DongKook Pharmaceutical (KOSDAQ:086450) Can Stay On Top Of Its Debt

May 06
We Think DongKook Pharmaceutical (KOSDAQ:086450) Can Stay On Top Of Its Debt

DongKook Pharmaceutical Co., Ltd. (KOSDAQ:086450) Vies For A Place In Your Dividend Portfolio: Here's Why

Apr 06
DongKook Pharmaceutical Co., Ltd. (KOSDAQ:086450) Vies For A Place In Your Dividend Portfolio: Here's Why

How Much Of DongKook Pharmaceutical Co., Ltd. (KOSDAQ:086450) Do Insiders Own?

Mar 15
How Much Of DongKook Pharmaceutical Co., Ltd. (KOSDAQ:086450) Do Insiders Own?

The DongKook Pharmaceutical (KOSDAQ:086450) Share Price Has Gained 136%, So Why Not Pay It Some Attention?

Feb 28
The DongKook Pharmaceutical (KOSDAQ:086450) Share Price Has Gained 136%, So Why Not Pay It Some Attention?

DongKook Pharmaceutical Co., Ltd.'s (KOSDAQ:086450) Stock Is Going Strong: Is the Market Following Fundamentals?

Feb 14
DongKook Pharmaceutical Co., Ltd.'s (KOSDAQ:086450) Stock Is Going Strong: Is the Market Following Fundamentals?

DongKook Pharmaceutical (KOSDAQ:086450) Seems To Use Debt Quite Sensibly

Feb 01
DongKook Pharmaceutical (KOSDAQ:086450) Seems To Use Debt Quite Sensibly

DongKook Pharmaceutical Co., Ltd. (KOSDAQ:086450) Shares Could Be 47% Below Their Intrinsic Value Estimate

Jan 19
DongKook Pharmaceutical Co., Ltd. (KOSDAQ:086450) Shares Could Be 47% Below Their Intrinsic Value Estimate

The Attractive Combination That Could Earn DongKook Pharmaceutical Co., Ltd. (KOSDAQ:086450) A Place In Your Dividend Portfolio

Jan 06
The Attractive Combination That Could Earn DongKook Pharmaceutical Co., Ltd. (KOSDAQ:086450) A Place In Your Dividend Portfolio

DongKook Pharmaceutical Co., Ltd. (KOSDAQ:086450) Looks Like A Good Stock, And It's Going Ex-Dividend Soon

Dec 24
DongKook Pharmaceutical Co., Ltd. (KOSDAQ:086450) Looks Like A Good Stock, And It's Going Ex-Dividend Soon

With EPS Growth And More, DongKook Pharmaceutical (KOSDAQ:086450) Is Interesting

Dec 21
With EPS Growth And More, DongKook Pharmaceutical (KOSDAQ:086450) Is Interesting

What Kind Of Investors Own Most Of DongKook Pharmaceutical Co., Ltd. (KOSDAQ:086450)?

Dec 08
What Kind Of Investors Own Most Of DongKook Pharmaceutical Co., Ltd. (KOSDAQ:086450)?

The DongKook Pharmaceutical (KOSDAQ:086450) Share Price Is Up 177% And Shareholders Are Boasting About It

Nov 23
The DongKook Pharmaceutical (KOSDAQ:086450) Share Price Is Up 177% And Shareholders Are Boasting About It

Revenue & Expenses Breakdown

How DongKook Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

KOSDAQ:A086450 Revenue, expenses and earnings (KRW Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 24789,11461,636319,08828,482
30 Jun 24764,67354,480317,64927,439
31 Mar 24747,01350,812316,52026,786
31 Dec 23730,99447,175311,20625,456
30 Sep 23709,54347,176305,66822,227
30 Jun 23692,79446,959300,53322,313
31 Mar 23676,77253,131288,12021,749
31 Dec 22661,64752,896278,30721,818
30 Sep 22645,74458,943272,13325,748
30 Jun 22631,06555,611262,67927,156
31 Mar 22615,97450,919260,72926,376
31 Dec 21594,19350,345256,85724,691
30 Sep 21585,74043,945250,92022,519
30 Jun 21588,36052,484246,58319,590
31 Mar 21572,39154,515238,37418,877
31 Dec 20559,10355,925231,52918,859
30 Sep 20544,68563,502223,29719,468
30 Jun 20520,46961,569214,31619,883
31 Mar 20502,39060,360205,88920,445
31 Dec 19482,28056,312198,00519,890
30 Sep 19456,23053,797189,05219,407
30 Jun 19436,29350,618181,46217,273
31 Mar 19418,58349,157174,16816,044
31 Dec 18400,80746,949164,93515,960
30 Sep 18391,80145,695156,62215,186
30 Jun 18378,38842,872151,84915,530
31 Mar 18366,90541,695147,89714,286
31 Dec 17354,76839,602145,19512,788
30 Sep 17342,29338,070142,84611,729
30 Jun 17330,62939,996136,54010,500
31 Mar 17320,34940,421129,5009,620
31 Dec 16309,69040,660124,55310,415
30 Sep 16302,00738,101120,87610,312
30 Jun 16292,76035,192116,63210,470
31 Mar 16275,17430,488110,37310,801
31 Dec 15259,93027,426103,73010,099
30 Sep 15244,76623,13999,40010,178
30 Jun 15234,68621,38095,40610,161
31 Mar 15228,19720,81192,18310,089
31 Dec 14226,01421,09890,6659,621
30 Sep 14224,39118,10790,3819,407
30 Jun 14220,61218,85987,7689,702
31 Mar 14218,09417,55287,6389,511
31 Dec 13213,08616,76486,1479,841

Quality Earnings: A086450 has high quality earnings.

Growing Profit Margin: A086450's current net profit margins (7.8%) are higher than last year (6.6%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: A086450's earnings have declined by 2.2% per year over the past 5 years.

Accelerating Growth: A086450's earnings growth over the past year (30.7%) exceeds its 5-year average (-2.2% per year).

Earnings vs Industry: A086450 earnings growth over the past year (30.7%) exceeded the Pharmaceuticals industry 22.3%.

Return on Equity

High ROE: A086450's Return on Equity (9.7%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 08:58
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

DongKook Pharmaceutical Co., Ltd. is covered by 10 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Mujinn LeeCape Investment & Securities Co., Ltd.
null nullDBS Bank Ltd
Hyuk Jin YoonEugene Investment & Securities Co Ltd.